The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Prognostic potential of MDM2 309T>G polymorphism in stage I lung adenocarcinoma.
Kimihiro Shimizu
No relevant relationships to disclose
Yasuaki Enokida
No relevant relationships to disclose
Jun Atsumi
No relevant relationships to disclose
Seiichi Kakegawa
No relevant relationships to disclose
Yoshiaki Takase
No relevant relationships to disclose
Seshiru Nakazawa
No relevant relationships to disclose
Toshiteru Nagashima
No relevant relationships to disclose
Yoichi Ohtaki
No relevant relationships to disclose
Kazumi Tanaka
No relevant relationships to disclose
Kyoichi Kaira
No relevant relationships to disclose
Izumi Takeyoshi
No relevant relationships to disclose